Aerie Pharma (AERI) Misses Q4 EPS by 27c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AAPL
2. AMD
3. PLTR
4. CRWD
5. DOX
6. VRTX
7. CHKP
8. ON
9. HNGE
10. INSP

Go back to Aerie Pharma (AERI) Misses Q4 EPS by 27c

Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

February 25, 2021 4:01 PM EST

2020 Net Revenues of $83.1 Million Increased 19% over 2019

Fourth Quarter Net Revenues of $24.7 Million or $80 Per Bottle

New Sustained Release Pan-VEGF Inhibitor Pipeline Candidate Announced Today

Conference Call and Webcast Today, February 25th, at 5:00 p.m. ET

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported... More